Ih Chang

TL;DR: The Wyeth Lederle as discussed by the authors determined the efficacy, safety and immunogenicity of the CRM197 pneumococcal conjugate vaccine against invasive disease caused by vaccine serotypes and to determine the effectiveness of this vaccine against clinical episodes of otitis media.

TL;DR: The safety, immunogenicity, and impact on carriage of a nonvalent pneumococcal vaccine given at ages 6, 10, and 14 weeks were examined in a double-blind, randomized, placebo-controlled trial in 500 infants in Soweto, South Africa.

TL;DR: PnCRM7 vaccine prevents vaccine serotype invasive pneumococcal disease even in a high risk population and other regions with similar disease burden should consider including this vaccine in the routine childhood vaccine schedule.

TL;DR: Primary immunization followed by a booster dose of PNCRM7 seemed to be acceptably safe and resulted in significant rises in antibody to all 7 serotypes, demonstrating effective stimulation of T-cell memory by the primary series of vaccinations.

TL;DR: This report analyses the various options with their relative merits and drawbacks and provides preliminary recommendations as guidance to regulatory agencies in evaluating these vaccines for the purposes of licensure.